Sandoz debuts US retail sales of Symjepi

9 July 2019

Sandoz, the generics and biosimilars division of Swiss pharma giant Novartis (NOVN: VX), today announced the US retail launch of Symjepi (epinephrine) 0.3mg and 0.15mg Injections, making both the adult and pediatric doses immediately available in local pharmacies across the nation.

These are small, single-dose, pre-filled syringe and device combination as an alternative to epinephrine auto-injectors for the emergency treatment of allergic reactions (Type 1), including anaphylaxis, a severe reaction that can lead to death if left untreated.

Sandoz also donated more than 4,000 packs (over 8,000 individual injections) of Symjepi 0.3mg Injection to Americares for distribution to free and charitable clinics across the USA. It is an alternative to Mylan’s (Nasdaq: MYL) EpiPen (epinephrine).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK